

RECEIVED

9

NOV 12 2002


PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box → ☒

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				TECH CENTER 1600/2900		
				Application Number	09/936,271	
				Filing Date	September 10, 2001	
				First Named Inventor	George M. Yousef et al	
				Group Art Unit	1645	
Examiner Name						
Sheet	1	of	9	Attorney Docket Number		MTS3USA

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
CO	AL	WO	WO98/20117	A1	Incyte Pharmaceuticals, Inc.	05/14/1998		

Examiner Signature		Date Considered	8/6/03
--------------------	---	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.


RECEIVED

NOV 12 2002

Please type a plus sign (+) inside this box → ☒

TECH CENTER 1600/2900 P0001B/08B (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/936,271
				Filing Date	September 10, 2001
				First Named Inventor	George M. Yousef et al
				Group Art Unit	1645
				Examiner Name	
Sheet	2	of	9	Attorney Docket Number	MTS3USA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
CA	AR	J. SIMMER et al, "Purification, Characterization, and Cloning of Enamel Matrix Serine Proteinase 1", J. Dent. Res., 77(2):377-386 (February, 1998)		
	AS	P. RIEGMAN et al, "Characterization of the Human Kallikrein Locus", Genomics, 14:6-11 (1992)		
	AT	L. SCHEDLICH et al, "Primary Structure of a Human Glandular Kallikrein Gene", DNA, 6(5):429-437 (1987)		
	AU	P. RIEGMAN et al, "Characterization of the Prostate-Specific Antigen Gene: a Novel Human Kallikrein-Like Gene", Biochem. Biophys. Res. Comm., 159(1):95-102 (February, 1989)		
	AV	G. YOUSEF et al, "Prostate/KLK-L1 is a New Member of the Human Kallikrein Gene Family, is Expressed in Prostate and Breast Tissues, and is Hormonally Regulated", Cancer Research, 59:4252-4256 (September, 1999)		
	AW	P. NELSON et al, Molecular Cloning and Characterization of Prostase, an Androgen-Regulated Serine Protease with Prostate-Restricted Expression", Proc. Natl. Acad. Sci. USA, 96(6):3114-3119 (March, 1999)		
	AX	S. STEPHENSON et al, "Localization of a New Prostate-Specific Antigen-Related Serine Protease Gene, KLK4, is Evidence for an Expanded Human Kallikrein Gene Family Cluster on Chromosome 19q13.3-13.4", J. Biol. Chem., 274(33):23210-23214 (August, 1999)		
	AY	E. DIAMANDIS et al, "The New Human Kallikrein Gene Family: Implications in Carcinogenesis", Trends in Endocrinology and Metabolism, 11(2):54-60 (2000)		
Examiner Signature				Date Considered
			8/6/03	


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

NOV 12 2002





PTO/SB/08B (08-00)

Please type a plus sign (+) inside this box → 

TECH CENTER 1600/2900

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/936,271
				Filing Date	September 10, 2001
				First Named Inventor	George M. Yousef et al
				Group Art Unit	1645
				Examiner Name	
Sheet	3	of	9	Attorney Docket Number	MTS3USA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AZ	G. YOUSEF et al, "Identification of Novel Human Kallikrein-Like Genes on Chromosome 19q13.3-q13.4", Anticancer Research, 19:2843-2852 (July, 1999)		
	AAR	B. DUPONT et al, "Assignment of Serine Protease 17 (PRSS17) to Human Chromosome Bands 19q13.3-q13.4 by in situ Hybridization", Cytogenet. Cell. Genet., 86:212-213 (April, 1999)		
	AAS	B. EVANS et al, "Structure and Chromosomal Localization of the Human Renal Kallikrein Gene", Biochemistry, 27(9):3124-3129 (1988)		
	AAT	J. CLEMENTS, "The Glandular Kallikrein Family of Enzymes: Tissue-Specific Expression and Hormonal Regulation", Endocr. Rev., 10(4):393-419 (November, 1989)		
	AAU	B. EVANS et al, "Mouse Glandular Kallikrein Genes", J. Biol. Chem., 262(17):8027-8034 (June, 1987)		
	AAV	C. DRINKWATER et al, "Kallikreins, Kinins and Growth Factor Biosynthesis", Trends Biochem. Sci. 13:169-172 (May, 1988)		
	AAW	P. ASHLEY et al, "Tissue-Specific Expression of Kallikrein-Related Genes in the Rat", Biochemistry, 24(17):4520-4527 (1985)		
	AAX	W. GERALD et al, "Sex Dimorphism and Hormonal Regulation of Rat Tissue Kallikrein mRNA", Biochem. Biophys. Acta., 867(1-2):16-23 (May, 1986) (Abstract only)		
	AAZ	A. ANISOWICZ et al, "A Novel Protease Homolog Differentially Expressed in Breast and Ovarian Cancer", Mol. Med., 2(5):624-636 (September, 1996)		
Examiner Signature			Date Considered	8/6/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

NOV 12 2002

Please type a plus sign (+) inside this box → ☐

TECH CENTER 1600/2000 (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/936,271
				Filing Date	September 10, 2001
				First Named Inventor	George M. Yousef et al
				Group Art Unit	1645
				Examiner Name	
Sheet	4	of	9	Attorney Docket Number	MTS3USA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
CO	AAZ	S. LITTLE et al, "Zyme, a Novel and Potentially Amyloidogenic Enzyme cDNA Isolated from Alzheimer's Disease Brain", J. Biol. Chem., 272(40):25135-25142 (October, 1997)		
	BR	K. YAMASHIRO et al, "Molecular Cloning of a Novel Trypsin-Like Serine Protease (Neurosin) Preferentially Expressed in Brain", Biochim. Biophys. Acta., 1350:11-14 (1997)		
	BS	X. LIU et al, "Identification of a Novel Serine Protease-Like Gene, the Expression of Which is Down-Regulated During Breast Cancer Progression", Cancer Res., 56:3371-3379 (July, 1996)		
	BT	L. LUO et al, "Structural Characterization and Mapping of the Normal Epithelial Cell-Specific 1 Gene", Biochem. Biophys. Res. Commun., 247(3):580-586 (1998)		
	BU	M. SCHACHTER et al, Pharmacol. Rev., 31:1-17 (1980)		
	BV	R. RICHARDS et al, "Mouse Glandular Kallikrein Genes", J. Biol. Chem., 257(6):2758-2761 (March, 1982)		
	BW	B. VAN LEEUWEN et al, "Mouse Glandular Kallikrein Genes - Identification, Structure, and Expression of the Renal Kallikrein Gene", J. Biol. Chem., 261(12):5529-5535 (April, 1986)		
	BX	B. EVANS et al, "Genes for the α and γ Subunits of Mouse Nerve Growth Factor are Contiguous", EMBO J., 4(1):133-138 (1985)		
✓	BY	I. ROGOZIN et al, "Gene Structure Prediction Using Information on Homologous Protein Sequence", Comput. Applic. Biosci., 12(3):161-170 (1996)		
Examiner Signature			Date Considered	8/6/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.


RECEIVED

NOV 12 2002

PTO/SB/08B (08-00)

Please type a plus sign (+) inside this box → ☐

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				TECH CENTER 1600/2900	
				Complete if Known	
				Application Number	09/936,271
				Filing Date	September 10, 2001
				First Named Inventor	George M. Yousef et al
				Group Art Unit	1645
				Examiner Name	
Sheet	5	of	9	Attorney Docket Number	MTS3USA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
CE	BZ	E. DIAMANDIS, "Prostate-Specific Antigen: Its Usefulness in Clinical Medicine", Trends Endocrinol. Metab., 9(8):310-316 (1998)			
	BBR	E. DIAMANDIS et al, "Detection of Prostate-Specific Antigen Immunoreactivity in Breast Tumors", Breast Cancer Res. Treat., 32:301-310 (1994)			
	BBS	T. ISHIKAWA et al, "Expression of α -Fetoprotein and Prostate-Specific Antigen Genes in Several Tissues and Detection of mRNAs in Normal Circulating Blood by Reverse Transcriptase-Polymerase Chain Reaction", Jpn. J. Clin. Oncol., 28(12):723-728 (1998)			
	BBT	D. IRWIN et al, "Structure and Evolution of the Bovine Prothrombin Gene", J. Mol. Biol., 212:31-45 (1988)			
	BBU	J. GOYAL et al, "The Role for NES1 Serine Protease as a Novel Tumor Suppressor", Cancer Res., 58(21):4782-4786 (November, 1998) (Abstract only)			
	BBV	E. DIAMANDIS et al, "Editorial: New Biological Functions of Prostate-Specific Antigen?", J. Clin. Endocrinol. Metab., 80(5):1515-1517 (1995)			
	BBW	J. REIFENBERGER et al, "Molecular Genetic Analysis of Oligodendroglial Tumors Shows Preferential Allelic Deletions on 19q and 1p", Am. J. Pathol., 145(5):1175-1190 (November, 1994)			
	BBX	Y. IIDA, "Quantification Analysis of 5'-Splice Signal Sequences in mRNA Precursors. Mutations in 5'-Splice Signal Sequence of Human β -Globin Gene and β -Thalassemia", J. Theor. Biol., 145:523-533 (1990)			
Examiner Signature				Date Considered	876103

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

RECEIVED


NOV 12 2002

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

TECH CENTER 1600/2900

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/936,271
				Filing Date	September 10, 2001
				First Named Inventor	George M. Yousef et al
				Group Art Unit	1645
				Examiner Name	
Sheet	6	of	9	Attorney Docket Number	MTS3USA


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
CO	BBY	J. CLEMENTS, "The Molecular Biology of the Kallikreins and their Roles in Inflammation", in S. Farmer (ed.), The Kinin System, pp. 71-97, New York (1997)			
	BBZ	S. YOSHIDA et al, "Sequence Analysis and Expression of Human Neuropilin cDNA and Gene", Gene, 213:9-16 (1998)			
	CR	T. TAKAYAMA et al, "Characterization of the Precursor of Prostate-Specific Antigen", J. Biol. Chem., 272(34):21582-21588 (August, 1997)			
	CS	M. DAYHOFF et al, "Atlas of Protein Sequence and Structure", Natl. Biomed. Res. Found., 5(Suppl 3):79-81 (1978)			
	CT	M. KOZAK, "An Analysis of 5'-Noncoding Sequences from 699 Vertebrate Messenger RNAs", Nucleic Acid Res., 15(20):8125-8148 (1987)			
	CU	N. PROUDFOOT et al, "3' Non-Coding Region Sequences in Eukaryotic Messenger RNA", Nature, 263:211-214 (September, 1976)			
	CV	H. YU et al, "Prognostic Value of Prostate-Specific Antigen for Women with Breast Cancer: a Large United States Cohort Study", Clin. Cancer Res., 4:1489-1497 (June, 1998)			
	CW	E. SAUTER et al, "Prostate-Specific Antigen Levels in Nipple Aspirate Fluid Correlate with Breast Cancer Risk", Cancer Epidemiol. Biomarkers Prev., 5:967-970 (December, 1996)			
✓	CX	A. FORTIER et al, "Antiangiogenic Activity of Prostate-Specific Antigen", J. Natl. Cancer Inst., 91(19):1635-1640 (October, 1999)			
Examiner Signature				Date Considered	876103

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

RECEIVED


NOV 12 2002

Please type a plus sign (+) inside this box → 

TECH CENTER 1600/2900 (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/936,271
				Filing Date	September 10, 2001
				First Named Inventor	George M. Yousef et al
				Group Art Unit	1645
				Examiner Name	
Sheet	7	of	9	Attorney Docket Number	MTS3USA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiners Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CQ	CY	A. KUMAR et al, "Expression of Pro Form of Prostate-Specific Antigen by Mammalian Cells and its Conversion to Mature, Active Form by Human Kallikrein 2", Cancer Res., 57:3111-3114 (August, 1997)	
	CZ	J. LOVGREN et al, "Activation of the Zymogen Form of Prostate-Specific Antigen by Human Glandular Kallikrein 2", Biochem. Biophys. Res. Commun., 238(2):549-555 (1997)	
	CCR	L. LAI et al, "Prostate-Specific Antigen in Breast Cyst Fluid: Possible Role of Prostate-Specific Antigen in Hormone-Dependent Breast Cancer", Int. J. Cancer, 66:743-746 (1996)	
	CCS	H. RITTENHOUSE et al, "Human Kallikrein 2 (hK2) and Prostate-Specific Antigen (PSA): Two Closely Related, but Distinct, Kallikreins in the Prostate", Crit. Rev. Clin. Lab. Sci., 35(4):275-368 (1998)	
	CCT	L. HANSSON et al, "Cloning, Expression, and Characterization of Stratum Corneum Chymotryptic Enzyme", J. Biol. Chem., 269(30):19420-19426 (July, 1994)	
	CCU	U. STENMAN, "New Ultrasensitive Assays Facilitate Studies on the Role of Human Glandular Kallikrein (hK2) as a Marker for Prostatic Disease", Clin. Chem., 45(6):753-754 (1999)	
✓	CCV	M. BLACK, "Development of an Ultrasensitive Immunoassay for Human Glandular Kallikrein with No Cross-Reactivity from Prostate-Specific Antigen", Clin. Chem., 45(6):790-799 (1999)	

Examiner Signature		Date Considered	8/6/03
-----------------------	---	--------------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.


RECEIVED

NOV 12 2002

Please type a plus sign (+) inside this box → ☒

TECH CENTER 1600/2900 (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/936,271
				Filing Date	September 10, 2001
				First Named Inventor	George M. Yousef et al
				Group Art Unit	1645
				Examiner Name	
Sheet	8	of	9	Attorney Docket Number	MTS3USA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
CO	CCW	L. UNDERWOOD et al, "Cloning of Tumor-Associated Differentially Expressed Gene-14, a Novel Serine Protease Overexpressed by Ovarian Carcinoma", Cancer Res., 59:4435-4439 (September, 1999)			
	CCX	N. HEUZE et al, "Molecular Cloning and Expression of an Alternative hKLK3 Transcript Coding for a Variant Protein of Prostate-Specific Antigen", Cancer Res., 59:2820-2824 (June, 1999)			
	CCY	P. RIEGMAN et al, "Identification and Androgen-Regulated Expression of Two Major Human Glandular Kallikrein-1 (hGK-1) mRNA Species", Mol. Cell Endocrinol., 76:181-190 (1991)			
	CCZ	L. CHEN et al, "Molecular Cloning and Characterization of a Novel Kallikrein Transcript in Colon and its Distribution in Human Tissues", Braz. J. Med. Biol. Res., 27:1829-1838 (1994)			
	DR	S. MITSUI et al, "A Novel Form of Human Neuropsin, a Brain-Related Serine Protease, is Generated by Alternative Splicing and is Expressed Preferentially in Human Adult Brain", Eur. J. Biochem., 260:627-634 (1999)			
	DS	R. BAFFA et al, "A Comparative Analysis of Prostate-Specific Antigen Gene Sequence in Benign and Malignant Prostate Tissue", Urology, 47:795-800 (1996)			
	DT	P. HENTTU et al, "Expression of the Gene Coding for Human Prostate-Specific Antigen and Related hGK-1 in Benign and Malignant Tumors of the Human Prostate", Int. J. Cancer, 45:654-660 (1990)			
Examiner Signature				Date Considered	8/6/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

RECEIVED


NOV 12 2002

Please type a plus sign (+) inside this box → ☒

TECH CENTER 1600/2900

PTO/SB/08B (08-00)

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/936,271
				Filing Date	September 10, 2001
				First Named Inventor	George M. Yousef et al
				Group Art Unit	1645
				Examiner Name	
Sheet	9	of	9	Attorney Docket Number	MTS3USA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiners Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
CE	DU	R. MCCORMACK et al, "Molecular Forms of Prostate-Specific Antigen and the Human Kallikrein Gene Family: a New Era", Urology, 45(5):729-744 (May, 1995)		
	DV	X. LIU et al, "Identification of Three New Alternate Human Kallikrein 2 Transcripts: Evidence of Long Transcript and Alternative Splicing", Biochem. Biophys. Res. Commun., 264(3):833-839 (1999)		
	DW	P. RIEGMAN et al, "Molecular Cloning and Characterization of Novel Prostate Antigen cDNA's", Biochem. Biophys. Res. Commun., 155(1):181-188 (August, 1988)		
	DX	A. LUNDWALL et al, "Molecular Cloning of Human Prostate Specific Antigen cDNA", FEBS Lett., 214(2):317-322 (April, 1987)		
	DY	N. ZARGHAMI et al, "Steroid Hormone Regulation of Prostate-Specific Antigen Gene Expression in Breast Cancer", Br. J. Cancer, 75(4):579-588 (1997)		
Examiner Signature			Date Considered	8/6/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

#14

PTO/SB/08B (08-00)

Approved for use through 4/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/936,271
				Filing Date	September 10, 2001
				First Named Inventor	Yousef et al.
				Group Art Unit	1636
				Examiner Name	C. Qian
Sheet	1	of	3	Attorney Docket Number	MTS3USA

 RECEIVED
 TECH. OFFICE
 03 JUN - 4 PM 2:00

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
CE	AA	US-5,786,148	07-28-1998	Bandman et al.	
CE	AB	US-5,922,321	07-13-1999	Bandman et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
CE	AM	WO-01/51633-A3	07-19-2001	Xu et al.		
CE	AN	WO-01/04143-A3	01-18-2001	Cabezon Silva et al.		

Examiner Signature		Date Considered	8/6/03
--------------------	---	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/936,271
				Filing Date	September 10, 2001
				First Named Inventor	Yousef et al.
				Group Art Unit	1636
				Examiner Name	C. Qian
Sheet	2	of	3	Attorney Docket Number	MTS3USA

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume, issue, number(s), publisher, city and/or country where published	T ²
CO	DZ	NADEAU et al., "Mouse on Human Homology Map", Mouse Genome, 89:31-36 (1991)	
	DDR	MORRIS et al., "Kallikrein and Renin: Molecular Biology and Biosynthesis", Clin. Sci., 61:351s-353s (December 1981)	
	DDS	GERALD et al., "Sex Dimorphism and Hormonal Regulation of Rat Tissue Kallikrein mRNA", Biochim. Biophys. Acta, 867:16-23 (May 27, 1986)	
	DDT	KIM et al., "Human Kallikrein Gene 5 (KLK5) Expression is an Indicator of Poor Prognosis in Ovarian Cancer", Brit. J. Cancer, 84(5):643-650 (March 2001)	
	DDU	OBIEZU et al., "Higher Human Kallikrein Gene 4 (KLK4) Expression Indicates Poor Prognosis of Ovarian Cancer Patients", Clin. Cancer Res., 7:2380-2386 (August 2001)	
	DDV	YOUSEF et al., "Identification and Characterization of KLK-L4, a New Kallikrein-like Gene that Appears to be Down-Regulated in Breast Cancer Tissues", J. of Biol. Chem., 275(16):11891-11898 (April 21, 2000)	
	DDW	YOUSEF et al., "Quantitative Expression of the Human Kallikrein Gene 9 (KLK9) in Ovarian Cancer: A New Independent and Favorable Prognostic Marker", Cancer Res., 61:7811-7818 (November 1, 2001)	
	DDX	YOUSEF et al., "The New Kallikrein-Like Gene, KLK-L2", J. Biol. Chem., 274(53): 37511-37516 (December 31, 1999)	
	DDY	YOUSEF et al., "The Expanded Human Kallikrein Gene Family: Locus Characterization and Molecular Cloning of a New Member, KLK-L3 (KLK9)", Genomics, 65:184-194 (April 15, 2000)	

Examiner Signature		Date Considered	8/6/03
--------------------	---	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/936,271
				Filing Date	September 10, 2001
				First Named Inventor	G. Yousef et al.
				Group Art Unit	1636
				Examiner Name	C. Qian
				Attorney Docket Number	MTS3USA
Sheet	3	of	3		

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume, issue, number(s), publisher, city and/or country where published	T ²
CQ	DDZ	YUSEF et al., "The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease", Endocrine Reviews, 22(2):184-204 (April 2001)	
↓	ER	HU et al., "Characterization of the Mouse and Human PRSS17 Genes, their Relationship to Other Serine Proteases, and the Expression of PRSS17 in Developing Mouse Incisors", Gene, 251:1-8 (June 13, 2000)	
↓	ES	GOYAL et al., "The Role of NES1 Serine Protease as a Novel Tumor Suppressor", Cancer Res., 58:4782-4786 (November 1, 1998)	
↓	ET	BRATTSAND et al., "Purification, Molecular Cloning, and Expression of a Human Stratum Corneum Trypsin-Like Serine Protease with Possible Function in Desquamation", J. Biol. Chem., 274(42): 30033-30040 (October 15, 1999)	

Examiner Signature	Date Considered	876103
--------------------	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.